CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Reports

We found 6105 result(s)

von Willebrand Factor [recombinant] (Vonvendi)

Last Updated: July 30, 2020
Result type: Reports
Product Line: Common Drug Review
Generic Name: von Willebrand Factor [recombinant]
Indications: von Willebrand disease, adults, treatment and perioperative management

  • Brand Name: Vonvendi
  • Manufacturer: Shire Pharma Canada ULC, now part of Takeda
  • Project Number: ST0639-000
  • Project Status: Active
  • Submission Type: New

emicizumab (Hemlibra)

Last Updated: July 29, 2020
Result type: Reports
Product Line: Common Drug Review
Generic Name: emicizumab
Indications: Bleeding prevention, hemophilia A

  • Brand Name: Hemlibra
  • Manufacturer: Hoffmann-La Roche Ltd.
  • Project Number: ST0651-000
  • Project Status: Active
  • Submission Type: New

dapagliflozin (Forxiga )

Last Updated: July 29, 2020
Result type: Reports
Product Line: Common Drug Review
Generic Name: dapagliflozin
Indications: Heart failure with reduced ejection fraction

  • Brand Name: Forxiga
  • Manufacturer: AstraZeneca Canada Inc.
  • Project Number: SR0642-000
  • Project Status: Active
  • Submission Type: New

fremanezumab (Ajovy)

Last Updated: July 28, 2020
Result type: Reports
Product Line: Common Drug Review
Generic Name: fremanezumab
Indications: migraine

  • Brand Name: Ajovy
  • Manufacturer: Teva Canada Innovation
  • Project Number: SR0641-000
  • Project Status: Received
  • Submission Type: New

eculizumab (Soliris)

Last Updated: July 29, 2020
Result type: Reports
Product Line: Common Drug Review
Generic Name: eculizumab
Indications: Neuromyelitis optica spectrum disorder

  • Brand Name: Soliris
  • Manufacturer: Alexion Pharma Canada Corp.
  • Project Number: SR0640-000
  • Project Status: Active
  • Submission Type: New

onasemnogene abeparvovec (Zolgensma)

Last Updated: July 28, 2020
Result type: Reports
Product Line: Common Drug Review
Generic Name: onasemnogene abeparvovec
Indications: Spinal muscular atrophy (SMA), pediatrics

  • Brand Name: Zolgensma
  • Manufacturer: Novartis Pharmaceuticals Canada Inc.
  • Project Number: SG0649-000
  • Project Status: Active
  • Submission Type: New

budesonide (Jorveza)

Last Updated: July 28, 2020
Result type: Reports
Product Line: Common Drug Review
Generic Name: budesonide
Indications: Eosinophilic esophagitis, adults

  • Brand Name: Jorveza
  • Manufacturer: AVIR Pharma Inc.
  • Project Number: SR0634-000
  • Project Status: Active
  • Submission Type: New

ofatumumab (TBC)

Last Updated: July 27, 2020
Result type: Reports
Product Line: Common Drug Review
Generic Name: ofatumumab
Indications: Multiple Sclerosis, relapsing

  • Brand Name: TBC
  • Manufacturer: Novartis Pharmaceuticals Canada Inc.
  • Project Number: SR0657-0000
  • Project Status: Pending
  • Submission Type: New

nintedanib (Ofev)

Last Updated: July 27, 2020
Result type: Reports
Product Line: Common Drug Review
Generic Name: nintedanib
Indications: chronic fibrosing interstitial lung diseases

  • Brand Name: Ofev
  • Manufacturer: Boehringer Ingelheim (Canada) Ltd.
  • Project Number: SR0654-000
  • Project Status: Received
  • Submission Type: New

vedolizumab (Entyvio)

Last Updated: July 27, 2020
Result type: Reports
Product Line: Common Drug Review
Generic Name: vedolizumab
Indications: Crohn’s disease

  • Brand Name: Entyvio
  • Manufacturer: Takeda Canada Inc.
  • Project Number: SR0647-000
  • Project Status: Received
  • Submission Type: New